(Q34595128)

3 August 2017

1 reference

title

Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents (English)

1 reference

3 August 2017

0 references

4

Ross J Baldessarini

1 reference

3 August 2017

James P Kelleher

1

1 reference

3 August 2017

Franca Centorrino

series ordinal

2

1 reference

3 August 2017

Matthew J Albert

series ordinal

3

1 reference

3 August 2017

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

16

1 reference

3 August 2017

249-261

1 reference

3 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200216040-00004

3 August 2017

0 references

cites work

Converting patients from brand-name clozapine to generic clozapine

1 reference

12 December 2020

Branded versus generic clozapine: bioavailability comparison and interchangeability issues

1 reference

12 December 2020

Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group

1 reference

12 December 2020

Off-label use of antipsychotic drugs.

1 reference

12 December 2020

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

12 December 2020

Fatty acid derivatives of clozapine: prolonged antidopaminergic activity of docosahexaenoylclozapine in the rat

1 reference

12 December 2020

Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether.

1 reference

12 December 2020

Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial

1 reference

12 December 2020

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland

1 reference

12 December 2020

An assessment of iloperidone for the treatment of schizophrenia

1 reference

12 December 2020

Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.

1 reference

12 December 2020

Effects of newer antipsychotics on extrapyramidal function

1 reference

12 December 2020

A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder

1 reference

12 December 2020

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

1 reference

12 December 2020

Pharmacologic treatment of schizophrenia: what the future holds

1 reference

12 December 2020

10.2165/00023210-200216040-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference